Executive SummaryAn agreement covering the development of recombinant elastase inhibitor for the treatment of emphysema was expanded to cover scale-up and commercial manufacturing. The arrangement calls for Synergen to deliver quantities of elastase inhibitor to Ciba-Geigy by the second half of 1987. The Boulder, Colo.-based biotech firm is currently constructing a $4 mil. pilot production facility that is scheduled for completion this summer.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.